公开(公告)号：EP1969134A1

公开(公告)日：2008-09-17

申请号：EP06847542.5

申请日：2006-12-08

申请人： Advancis Pharmaceutical Corporation

发明人： TREACY, Donald ,  POTTS, Alan R. ,  FLANNER, Henry H. ,  BURNSIDE, Beth A. ,  TOLLE-SANDER, Sanna ,  CLAUSEN, Susan P.

IPC分类号： C12P21/04

CPC分类号： A61K9/2081 ,  A61K9/5026 ,  A61K9/5084

摘要： Disclosed are amoxicillin products comprising at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier. In some embodiments, when administered to a patient or subject in the fed state the amoxicillin products exhibit a pharmacokinetic profile for amoxicillin in the plasma characterized as follows: (1) the ratio of the portion of the AUC as measured from 2 hours post-administration to 5 hours post-administration to the portion of the AUC as measured from administration to 2 hours post- administration is at least 2.0: 1 : and (2) the ratio of the portion of the AUC as measured from 5 hours post-administration to 12 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 1.1:1. In additional embodiments the amoxicillin products exhibit a mean in-vitro dissolution profile within a defined range characterized as follows: 1) the percent dissolved at 0.25 hours is between 25 and 55 percent; 2) the percent dissolved at 0.5 hours is between 30 and 60 percent; 3) the percent dissolved at 1 hour is between 50 and 85 percent; 4) the percent dissolved at 1.5 hours is between 70 and 95 percent; and 5) the percent dissolved at 2 hours is at least 85 percent. In preferred embodiments the amoxicillin products exhibit both of these characteristics.